• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

淋巴靶向药物递送系统在抗肿瘤转移治疗中的研究进展

冯旸, 徐霄, 莫然

冯旸, 徐霄, 莫然. 淋巴靶向药物递送系统在抗肿瘤转移治疗中的研究进展[J]. 中国药科大学学报, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
引用本文: 冯旸, 徐霄, 莫然. 淋巴靶向药物递送系统在抗肿瘤转移治疗中的研究进展[J]. 中国药科大学学报, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
Citation: FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406

淋巴靶向药物递送系统在抗肿瘤转移治疗中的研究进展

基金项目: 国家自然科学基金资助项目(No.81673381)

Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis

Funds: This study was supported by the National Natural Science Foundation of China (No.81673381)
  • 摘要: 淋巴转移是肿瘤转移的主要途径之一,传统药物治疗肿瘤淋巴转移的局限在于药物在淋巴转移灶的浓度低导致疗效不佳。纳米药物递送系统在增强药物靶向性、提高药物生物利用度、降低药物不良反应等方面发挥着重要作用。本综述介绍了淋巴系统的组成和功能,阐述了淋巴系统在肿瘤转移中的作用,列举了现有的抗肿瘤淋巴转移治疗手段及局限性,重点阐述被动、主动以及抗原递呈细胞介导的淋巴靶向药物递送系统在抗肿瘤转移治疗中的研究进展。
    Abstract: Lymphatic metastasis is one of the main routes of tumor metastasis. The limitation of traditional medicine in the treatment of lymphatic tumor metastasis lies in the low concentration of the drug in lymphatic metastases resulting in poor efficacy. Nanocarrier-based drug delivery system plays an important role in enhancing drug targeting, improving drug bioavailability, and reducing side effects. This review introduces the composition and function of the lymphatic system as well as its role in tumor metastasis, enumerates the present therapeutic means and limitations of anti-tumor lymphatic metastasis, and focuses on the recent advances in the passive, active and antigen-presenting cell-mediated lymphatic targeted drug delivery systems in tumor metastasis are highlighted.
  • [1] Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms[J]. Cell,2011,147(2):275-292.
    [2] Gupta GP, Massague J. Cancer metastasis: building a framework[J]. Cell,2006,127(4):679-695.
    [3] Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites[J]. Nat Rev Cancer,2002,2(8):563-572.
    [4] Li MR, Li T, Mo R. Recent progress in targeted drug delivery nanosystems for pancreatic cancer treatment[J]. APSB,2018,53(7):1090-1099.
    [5] Wong SY, Hynes RO. Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide?[J]. Cell Cycle,2006,5(8):812-817.
    [6] Cote B, Rao D, Alany RG, et al. Lymphatic changes in cancer and drug delivery to the lymphatics in solid tumors[J]. Adv Drug Delivery Rev,2019,144:16-34.
    [7] Ryan TJ. Structure and function of lymphatics[J]. J Invest Dermatol,1989,93(2 Suppl):18s-24s.
    [8] Card CM, Yu SS, Swartz MA. Emerging roles of lymphatic endothelium in regulating adaptive immunity[J]. J Clin Invest,2014,124(3):943-952.
    [9] Swartz MA. The physiology of the lymphatic system[J]. Adv Drug Deliv Rev,2001,50(1):3-20.
    [10] Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes[J]. Oncogene,2007,26(32):4679-4688.
    [11] Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis[J]. Nature,2001,410(6824):50-56.
    [12] Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes[J]. Cancer Res,2004,64(11):4010-4017.
    [13] Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread[J]. FASEB J,2002,16(9):922-934.
    [14] White RR, Stanley WE, Johnson JL, et al. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis[J]. Ann Surg,2002,235(6):879-887.
    [15] Fife K, Thompson JF. Lymph-node metastases in patients with melanoma: what is the optimum management?[J]. Lancet Oncol,2001,2(10):614-621.
    [16] Ryan GM, Kaminskas LM, Bulitta JB, et al. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin[J]. J Control Release,2013,172(1):128-136.
    [17] Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update[J]. Adv Drug Deliv Rev,2008,60(6):702-716.
    [18] Shao K, Singha S, Clemente-Casares X, et al. Nanoparticle-based immunotherapy for cancer[J]. ACS Nano,2015,9(1):16-30.
    [19] Cho K, Wang X, Nie SM, et al. Therapeutic nanoparticles for drug delivery in cancer[J]. Clin Cancer Res,2008,14(5):1310-1316.
    [20] Wang MY, Li T, Jiang SG, et al. Recent advances in liposome-based co-delivery systems for combination cancer therapy[J]. Chin J Bioprocess Engineer(生物加工过程),2018,16(5):33-41.
    [21] Chen X, Kang Y, Wu J, et al. Advances in biodegradable functional polymers based protein drug delivery system [J]. J China Pharm Univ (中国药科大学学报),2017,48(2):142-149.
    [22] Abellan-Pose R, Csaba N, Alonso MJ. Lymphatic targeting of nanosystems for anticancer drug therapy[J]. Curr Pharm Des,2016,22(9):1194-1209.
    [23] Attili-Qadri S, Karra N, Nemirovski A, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption[J]. Proc Natl Acad Sci U S A,2013,110 (43):17498-17503.
    [24] Chen JH, Wang L, Yao Q, et al. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer[J]. Breast Cancer Res,2004,6(4):474-477.
    [25] Harvey AJ, Kaestner SA, Sutter DE, et al. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs[J]. Pharm Res,2011,28(1):107-116.
    [26] Oussoren C, Velinova M, Scherphof G, et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. IV. Fate of liposomes in regional lymph nodes[J]. Biochim Biophys Acta,1998,1370(2):259-272.
    [27] Thomas SN, Schudel A. Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery[J]. Curr Opin Chem Eng,2015,7:65-74.
    [28] Ryan GM, Kaminskas LM, Porter CJ. Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers[J]. J Control Release,2014,193:241-256.
    [29] Rao DA, Forrest ML, Alani AW, et al. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery[J]. J Pharm Sci,2010,99 (4):2018-2031.
    [30] Zhang YN, Lazarovits J, Poon W, et al. Nanoparticle size influences antigen retention and presentation in lymph node follicles for humoral immunity[J]. Nano Lett,2019,19(10):7226-7235.
    [31] Cabral H, Makino J, Matsumoto Y, et al. Systemic targeting of lymph node metastasis through the blood vascular system by using size-controlled nanocarriers[J]. ACS Nano,2015,9(5):4957-4967.
    [32] Moghimi SM. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes[J]. Biomaterials,2006,27(1):136-144.
    [33] Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics[J]. Adv Drug Deliv Rev,1995,17(1):129-148.
    [34] Zeng Q, Jiang H, Wang T, et al. Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses[J]. J Control Release,2015,200:1-12.
    [35] Trevaskis NL, Kaminskas LM, Porter CJ. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity[J]. Nat Rev Drug Discov,2015,14(11):781-803.
    [36] Chen JH, Ling R, Yao Q, et al. Effect of small-sized liposomal adriamycin administered by various routes on a metastatic breast cancer model[J]. Endocr Relat Cancer,2005,12(1):93-100.
    [37] Doddapaneni BS, Kyryachenko S, Chagani SE, et al. A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma[J]. J Control Release,2015,220(Pt A):503-514.
    [38] Zhang ZP, Tongchusak S, Mizukami Y, et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery[J]. Biomaterials,2011,32(14):3666-3678.
    [39] Kaminskas LM, Kota J, McLeod VM, et al. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats[J]. J Control Release,2009,140(2):108-116.
    [40] Jiang H, Wang Q, Li L, et al. Turning the old adjuvant from gel to nanoparticles to amplify CD8 + T cell responses [J]. Adv Sci,2017,5(1):1700426.doi: 10.1002/advs.201700426.
    [41] Hong XY, Zhong XF, Du GS, et al. The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency [J]. Sci Adv,2020,6(25): eaaz4462.
    [42] Laakkonen P, Porkka K, Hoffman JA, et al. A tumor-homing peptide with a targeting specificity related to lymphatic vessels[J]. Nat Med,2002,8(7):751-755.
    [43] Yan ZQ, Wang F, Wen ZY, et al. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor[J]. J Control Release,2012,157(1):118-125.
    [44] Luo GP, Yu XJ, Jin C, et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors[J]. Int J Pharm,2010,385(1/2):150-156.
    [45] Jin L, Nakajima M, Nicolson GL. Immunochemical localization of heparanase in mouse and human melanomas[J]. Int J Cancer,1990,45(6):1088-1095.
    [46] Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion[J]. Biochim Biophys Acta,2001,1471(3):99-108.
    [47] Dafni H, Cohen B, Ziv K, et al. The role of heparanase in lymph node metastatic dissemination: dynamic contrast-enhanced MRI of Eb lymphoma in mice[J]. Neoplasia,2005,7(3):224-233.
    [48] Ye TT, Jiang XW, Li J, et al. Low molecular weight heparin mediating targeting of lymph node metastasis based on nanoliposome and enzyme-substrate interaction[J]. Carbohydr Polym,2015,122:26-38.
    [49] Yang WH, Luo DF, Wang SX, et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis[J]. Clin Cancer Res,2008,14(17):5494-5502.
    [50] Wei R, Jiang GY, Lv MQ, et al. TMTP1-modified indocyanine green-loaded polymeric micelles for targeted imaging of cervical cancer and metastasis sentinel lymph node in vivo[J]. Theranostics,2019,9(24):7325-7344.
    [51] Lim HY, Thiam CH, Yeo KP, et al. Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL[J]. Cell Metab,2013,17 (5):671-684.
    [52] Kuai R, Sun XQ, Yuan WM, et al. Subcutaneous nanodisc vaccination with neoantigens for combination cancer immunotherapy[J]. Bioconjugate Chem,2018,29(3):771-775.
    [53] Kuai R, Ochyl LJ, Bahjat KS, et al. Designer vaccine nanodiscs for personalized cancer immunotherapy[J]. Nat Mater,2017,16(4):489-496.
    [54] Caminschi I, Maraskovsky E, Heath WR. Targeting dendritic cells in vivo for cancer therapy[J]. Front Immunol,2012,3:13.
    [55] Tacken PJ, de Vries IJM, Torensma R, et al. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting[J]. Nat Rev Immunol,2007,7(10):790-802.
    [56] Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines[J]. Trends in Immunology,2006,27(12):573-579.
    [57] Huang SQ, Shi M, He YN, et al. Construction and in vitro evaluation of DC-targeted aptamer-modified Pseudomonas aeruginosa DNA vaccine delivery system [J]. J China Pharm Univ (中国药科大学学报),2019,50(6):743-752.
    [58] Zhang LH, Wu SJ, Qin Y, et al. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy[J]. Nano Lett,2019,19(7):4237-4249.
    [59] Wang C, Liu P, Zhuang Y, et al. Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory[J]. Vaccine,2014,32(42):5475-5483.
计量
  • 文章访问数:  401
  • HTML全文浏览量:  11
  • PDF下载量:  727
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-06-10
  • 刊出日期:  2020-08-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭